No abstract available.
Blood Component Transfusion*

A retrospective study on the use of total blood and blood preparations from 2001 to November 2002 period was reported. 144,394 units of blood were used, among them, total blood accounts for 41.50%, sedimented red blood cells 31.25%, washed red blood cells 0.88%, fresh freezing plasma 4.60%, concentrated blood plaquettes 13.34%, fresh plasma intensified with white blood cells 4.17%, freezing precipitation with high rate of VIU factor 4.17%. A higher amount of total blood was used in comparing of that of the past year. High efficacy of the use of blood was toted
Blood ; Blood Component Transfusion ; hospitals

Allergic transfusion reaction (ATR) caused by plasma transfusion is one of the main adverse transfusion reactions, and severe allergic reactions may even endanger the patient's life. Currently, ATR is mainly prevented and controlled by drug prevention and symptomatic treatment, and there still lack of preventive measures such as in vitro experiments. It has been shown that mast cells and basophils are the main effector cells of allergic reactions, and histamine is one of the main mediators of IgE-mediated allergic reactions. Some experiments can be used to identify patients with allergies or plasma components containing allergens, such as detection of serum-specific IgE, IgA, anti-IgA antibody, tryptase and histamine, mast cell degranulation test, basophil activation test, and so on. The basophil activation test can also be used for functional matching of plasma in vitro. Research of in vitro experiment of ATR is good for directing the precise infusion of plasma, reducing waste of resources, and avoiding the risk of blood transfusion. As a pre-transfusion laboratory test for clinical use, in vitro experiment of functional matching provides a new way to prevent ATR.
Blood Component Transfusion ; Blood Transfusion ; Humans ; Hypersensitivity ; Plasma ; Transfusion Reaction

No abstract available.
Arm* ; Blood Component Transfusion* ; Hospitals, General*

OBJECTIVE: To investigate the related factors of adverse reactions of blood transfusion, and clinical precautions so as to reduce the adverse reactions. METHODS: Data of 2108 patients with allogeneic transfusion in our hospital from January 2017 to June 2017 collected and analyzed. RESULTS: These patients received 15 244 time of blood transfusion, and 213 time of adverse reactions occurred in 178 patients in totality, the incidence is 1.4%, and there was no significant difference between the male (1.31%) and female (1.53%). The main type of transfusion reaction were allergy (73.23%), FNHTR (11.74%) and TACO (10.80%). Among all kinds of blood components, the incidence of adverse reactions of apheresis platelet transfusion was the highest (4.31%), significantly higher than that of cryoprecipitate and other blood components. The incidence rate of adverse reactions of blood transfusion in the hematopathy patients was 2.56%, significantly higher than that of immune diseases (1.48%), cancer diseases (1.28%) and other diseases (1.08%), (P＜0.01). The rate of transfusion history of apheresis platelets was 42.67% (the incidence of adverse reactions was 4.31%), significantly higher than other groups (P＜0.01); the rate of transfusion history of cryoprecipitate was 4.11% (the incidence of adverse reaction was 0.45%), significantly lower than other groups (P＜0.05). Among the disease types, the rate of transfusion history in the hematopathy patients was 48.79% (the incidence of adverse reaction was 2.56%), significantly higher than that of other groups (P＜0.01). The incidence of drug allergy in patients with the adverse reactions to blood transfusion was 11.25%, significantly higher than that of patients without adverse reactions (4.71%) (P＜0.01). CONCLUSION The main risk factors of adverse reactions of blood transfusion are as follows: blood varieties, disease type, transfusion history and drug allergy history. For the patients with transfusion, multiple factors should be controlled, so as to reduce the adverse reactions.
Blood Component Transfusion ; Blood Transfusion ; Female ; Humans ; Hypersensitivity ; Male ; Platelet Transfusion ; Transfusion Reaction

OBJECTIVE: To study the clinical effects of preoperative autologous blood donation (PABD) in selective general surgery. METHODS: Paired study was performed in PABD group with 70 PABD cases screened from selective general surgery during the period from November 2017 to August 2018 in our hospital, and the control group included 70 cases without preoperative autologous blood donation, the baseline data before surgery were not significantly different. The transfusion quantities of allogeneic RBC and plasma, the levels of perioperative hemoglobin and platelets, the time and expense of hospitalization were compared between two groups. RESULTS: The levels of Hb and Plt in PABD group before and after blood collection were determined as follows: 138.26±14.73 g/L vs 127.52±13.36 g/L (P＜0.05) and (221.67±52.86)×10/L vs (198.35±52.65)×10/L (P＞0.05) respectively. The analysis of allo-RBC and allo-plasma transfusion in PABD group and control group showed that: the quantity of allogeneic RBC transfusion was 0.20±0.71 U and 0.89±0.97 U, and the quantity of allogeneic plasma transfusion was 30.43±100.81 ml and 106.52±152.61 ml (P＜0.05) respectirdy during perioperation. The comparison results of preoperative Hb and plt in PABD group and control group were 135.65±14.16 g/L vs 134.15±11.98 g/L and (270.36±58.28)×10/L vs (271.67±65.02) ×10/L respectively. The levels of postoperative Hb and plt in PABD group and control group were 120.24±14.40 g/L vs 121.20±14.30 g/L at 1 d after operation, and (241.80±63.58)×10/L vs (241.30±69.11)×10/L at 1 d after operation respectively; 123.15±13.80 g/L vs 121.65±14.33 g/L at 3 d after operation and (251.26±72.94)×10/L vs (255.54±73.85)×10/L at 3 d after operation; 122.78±13.92 g/L and 122.00±13.82 g/L (before discharge) and (262.50±80.96)×10/L and (264.56±71.08)×10/L (before discharge, platelet). These data were not statistically different (P＞0.05). The hospitalization time was 14.84±3.37 days and 14.84±2.24 days, respectively, without statistical difference (P＞0.05) in two groups. The expenses of hospitalization and the blood transfusion in two groups were 50627.27±9889.45 RMB and 50979.43±8195.00 RMB; 354.39±362.57 RMB and 684.02±425.53 RMB (P＜0.05). CONCLUSION The application of PABD reduces the use of allogeneic blood and costs for patients undergoing selective surgery with blood losts of 1000 ml.
Blood Component Transfusion ; Blood Donors ; Blood Transfusion ; Blood Transfusion, Autologous ; Humans ; Plasma

BACKGROUND: Transfusion service, as a task directly affecting the patient's life, must be performed as expeditiously as possible. However, for various reasons, we have experienced difficulty in supplying blood products in a timely manner. In this study, we analyzed the turnaround time (TAT) of blood issue and attempted to find a solution. METHODS: We evaluated the TATs for the request and preparation of blood transfusions in our hospital from January to December 2011. The time of blood issue, from acceptance of the request to preparation in the blood bank, was calculated from computerized medical records. In cases in which the TAT exceeded 24 hours, we investigated the type of blood component and the cause of the delay. RESULTS: A total of 12,856 units of blood were issued during the study year. Of these, 1,333 units (10.4%) had TATs exceeding 24 hours. These units included 148 units of red blood cells (RBC) (2.1%), 49 units of leukocyte-filtered red blood cells (F-RBC) (69.0%), 92 units of fresh frozen plasma (FFP) (3.9%), six units of cryoprecipitates (CRYO) (7.4%), 818 units of platelets (PLT) (27.1%), and 220 units of apheresis platelets (A-PLT) (66.5%). The preparation times for PLT and A-PLT were more delayed. The cause of the delays was lack of inventory at the blood center. CONCLUSION: We recommend that the blood center keep blood products even at the risk that they will be discarded for exceeding the expiration date. In addition, we suggest that testing of donated blood be performed within the region.
Blood Banks ; Blood Component Removal ; Blood Platelets ; Blood Transfusion ; Erythrocytes ; Medical Records Systems, Computerized ; Plasma

BACKGROUND: Transfusion service, as a task directly affecting the patient's life, must be performed as expeditiously as possible. However, for various reasons, we have experienced difficulty in supplying blood products in a timely manner. In this study, we analyzed the turnaround time (TAT) of blood issue and attempted to find a solution. METHODS: We evaluated the TATs for the request and preparation of blood transfusions in our hospital from January to December 2011. The time of blood issue, from acceptance of the request to preparation in the blood bank, was calculated from computerized medical records. In cases in which the TAT exceeded 24 hours, we investigated the type of blood component and the cause of the delay. RESULTS: A total of 12,856 units of blood were issued during the study year. Of these, 1,333 units (10.4%) had TATs exceeding 24 hours. These units included 148 units of red blood cells (RBC) (2.1%), 49 units of leukocyte-filtered red blood cells (F-RBC) (69.0%), 92 units of fresh frozen plasma (FFP) (3.9%), six units of cryoprecipitates (CRYO) (7.4%), 818 units of platelets (PLT) (27.1%), and 220 units of apheresis platelets (A-PLT) (66.5%). The preparation times for PLT and A-PLT were more delayed. The cause of the delays was lack of inventory at the blood center. CONCLUSION: We recommend that the blood center keep blood products even at the risk that they will be discarded for exceeding the expiration date. In addition, we suggest that testing of donated blood be performed within the region.
Blood Banks ; Blood Component Removal ; Blood Platelets ; Blood Transfusion ; Erythrocytes ; Medical Records Systems, Computerized ; Plasma

A recently increased need to a computerized program for correct management of grouping and dealing of bloods at small to mize hospitals made us develope the blood bank management program with a personal computer. Some hardwares(PC 486, bar code reader and printer) and softwares(Microsoft Foxpro version 2.5 for main development and Hanmac 2.5 for Korean BIOS) were used as materials, and frequent upgrades were performed during the develpment period. The program was consisted of eight main functions including grouping, input, output, reinput and expire of bloods, and autotransfusion, apheresis and directed transfusion. The program may be a good tool to reduce blood accidents and to enhance quality of blood banks at small to medium size hospitals.
Automatic Data Processing ; Blood Banks* ; Blood Component Removal ; Blood Transfusion, Autologous ; Humans ; Microcomputers*

OBJECTIVE: To analyze the use of blood products in patients at different ages. METHODS: The clinical datas of the 10 784 patients transfused in Sichuan provincial people's hospital at 2017-2018 were retrospectively analyzed, and the basic condition of clinical blood using was statistically described. The patients were divided into the groups according to age and disease, then the use of various blood products in the patients with different diseases in different age groups was analyzed. RESULTS: The age of blood transfusion patients was mainly 40-80 years old, and the most common disease was tumor(about 28%). The average annual transfusion volumes of red blood cells(RBC) were 24 936.5 U, of platelets(PLT) were 3 795 therapeutic doses of plasma were 2 455 500 ml, of cryoprecipitate were 3 461.5 U in our hospital. Most patients with hematologic malignancies and liver cirrhosis were transfused with two or more blood productions. For the patients with hematologic malignancies, the irradiated RBC (76.4%), PLT (67.8%), and suspended RBC (59.9%) were commonly used. And for liver cirrhosis patients, the suspended RBC (64.2%) and fresh frozen plasma(FFP) (59.4%) were commonly used. For the patients with trauma and chronic kidney disease(CKD), the suspended RBC (95.7% and 91.5%, respectively) was commonly used. In hematologic malignancies patients, the transfusion volume of irradiated RBC, PLT and FFP in the patients aged ≥60 years old was lower than that in patients aged<60 years old (P<0.05); in trauma patients, the transfusion volume of suspended RBC in the patients aged ≥60 years old was lower than that in patients aged<60 years old (P<0.05). In hematologic malignancies, trauma and liver cirrhosis patients, the proportion of PLT and/or plasma transfusion in the patients aged ≥60 years old was lower than that in patients aged<60 years old (P<0.05), and the elderly patients were more likely to receive RBC transfusion only. CONCLUSION There is a difference in the distribution of blood product between the patients aged<60 years old and ≥60 years old in the same disease, and it is more likely that the elderly patients (aged ≥60 years old) receive RBC transfusion only, and correction of hypoxia is a major clinical consideration, so blood using plans should be made according to the patient population, moreover, the different transfusion strategies should be developed for different population to maximize the efficiency of blood using.
Adult ; Aged ; Aged, 80 and over ; Blood Component Transfusion ; Blood Transfusion ; Hospitals ; Humans ; Middle Aged ; Plasma ; Retrospective Studies